skip to main content

United Therapeutics Corporation to Report Second Quarter 2017 Financial Results Before The Market Opens on Thursday, July 27, 2017

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 21, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2017 financial results before the market opens on Thursday, July 27, 2017.

United Therapeutics will host a teleconference on Thursday, July 27, 2017, at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 51149275.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.  [uthr-g]

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-second-quarter-2017-financial-results-before-the-market-opens-on-thursday-july-27-2017-300492320.html

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an...
The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled SILVER SPRING, Md...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended...
If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH) This investigational therapy combines two potent...
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release...